Security
CARISMA THERAPEUTICS INC Common Stock · CARM
CARMOTCCommon stockCurrentCIK 1485003Updated Oct 6, 2026
Name history
Sesen Bio, Inc. · through Mar 6, 2023Eleven Biotherapeutics, Inc. · through May 16, 2018
CARM price & chart
Loading TradingView…
OTC:CARM on TradingView ↗About the company
Carisma Therapeutics is a biotechnology company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis and cancer. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www. Carismatx.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,554,000Source | 42,058,000Source | 106,784,000Source | 5,012,000Source | 59,339,000Source | 133,013,000Source | 15,953,000Source | 73,795,000Source | 30,458,000Source | 89,554,000Source | 189,174,000Source | 240,747,000Source |
| Property, Plant and Equipment, NetUSD | — | — | 7,379,000Source | — | — | 7,590,000Source | — | — | — | — | 0Source | 43,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 13,064,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 14,700,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,777,000Source | 26,881,000Source | 83,132,000Source | 1,999,000Source | 40,362,000Source | 76,353,000Source | 7,740,000Source | 56,515,000Source | 17,909,000Source | 77,605,000Source | 112,553,000Source | 162,636,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 21,011,000Source |
| Assets, CurrentUSD | 5,870,000Source | 34,137,000Source | 97,565,000Source | 4,295,000Source | 50,721,000Source | 122,200,000Source | 13,954,000Source | 60,953,000Source | 23,825,000Source | 80,471,000Source | 189,144,000Source | 205,605,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,090,000Source | 7,256,000Source | 3,428,000Source | 2,285,000Source | 10,359,000Source | 5,122,000Source | 2,901,000Source | 4,438,000Source | 5,916,000Source | 2,866,000Source | 400,000Source | 18,476,000Source |
| Operating Lease, Right-of-Use AssetUSD | 684,000Source | 2,322,000Source | 1,664,000Source | 717,000Source | 1,945,000Source | 3,047,000Source | 1,999,000Source | 5,150,000Source | 2,040,000Source | 2,173,000Source | 0Source | — |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 123,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,421,000Source | 53,184,000Source | 60,486,000Source | 51,017,000Source | 58,979,000Source | 66,308,000Source | 52,615,000Source | 62,900,000Source | 58,367,000Source | 63,022,000Source | 30,984,000Source | 69,037,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 41,000Source | 41,000Source | 40,000Source | 41,000Source | 41,000Source | 40,000Source | 41,000Source | 41,000Source | 41,000Source | 40,000Source | 202,000Source | 199,000Source |
| Additional Paid in CapitalUSD | 278,994,000Source | 276,777,000Source | 270,029,000Source | 278,573,000Source | 275,561,000Source | 269,141,000Source | 278,142,000Source | 274,934,000Source | 277,629,000Source | 271,594,000Source | 494,675,000Source | 487,768,000Source |
| Retained Earnings (Accumulated Deficit)USD | -279,902,000Source | -287,944,000Source | -224,144,000Source | -324,619,000Source | -275,242,000Source | -202,741,000Source | -314,845,000Source | -264,080,000Source | -305,579,000Source | -245,102,000Source | -336,141,000Source | -316,257,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 373,000Source | — | — | 265,000Source | — | — | — | 0Source | -546,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | — | — | 46,298,000Source | — | — | 66,705,000Source | — | — | — | 26,532,000Source | 158,190,000Source | 171,710,000Source |
| Liabilities and EquityUSD | 6,554,000Source | 42,058,000Source | 106,784,000Source | 5,012,000Source | 59,339,000Source | 133,013,000Source | 15,953,000Source | 73,795,000Source | 30,458,000Source | 89,554,000Source | 189,174,000Source | 240,747,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,812,000Source | 10,558,000Source | 12,951,000Source | 8,950,000Source | 15,617,000Source | 17,973,000Source | 10,447,000Source | 13,141,000Source | 16,055,000Source | 15,908,000Source | 30,984,000Source | 11,568,000Source |
| Operating Lease, Liability, CurrentUSD | 153,000Source | 1,386,000Source | 856,000Source | 703,000Source | 1,179,000Source | 2,486,000Source | 998,000Source | 2,474,000Source | 832,000Source | 1,391,000Source | 0Source | — |
| Accounts Payable, CurrentUSD | 5,571,000Source | 1,728,000Source | 2,409,000Source | 4,757,000Source | 2,033,000Source | 2,487,000Source | 3,251,000Source | 2,166,000Source | 2,081,000Source | 3,933,000Source | 1,233,000Source | 2,853,000Source |
| Operating Lease, Liability, NoncurrentUSD | 609,000Source | 761,000Source | 891,000Source | 648,000Source | 795,000Source | 920,000Source | 687,000Source | 2,759,000Source | 724,000Source | 860,000Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 3,969,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 519,000Source | 1,176,000Source | 169,000Source | 815,000Source | 1,809,000Source | 231,000Source | 1,131,000Source | 318,000Source | 926,000Source | — | 0Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | 0Source | — | — | 0Source | — | — | — | 0Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,088,000Source | 4,542,000Source | 7,026,000Source | 2,528,000Source | 9,241,000Source | 9,614,000Source | 4,705,000Source | 4,729,000Source | 7,448,000Source | 7,662,000Source | 29,636,000Source | 8,255,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 2,800,000Source | 26,900,000Source | 94,100,000Source | 2,000,000Source | 40,400,000Source | 117,100,000Source | 7,700,000Source | 56,500,000Source | 17,900,000Source | 77,600,000Source | 166,900,000Source | — |
| Deferred Revenue, CurrentUSD | 0Source | 682,000Source | 1,185,000Source | 0Source | 659,000Source | 1,416,000Source | 0Source | 1,189,000Source | 3,729,000Source | 1,413,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 0Source | 41,250,000Source | 45,000,000Source | 41,250,000Source | 41,250,000Source | 45,000,000Source | 41,250,000Source | 45,000,000Source | 41,250,000Source | 45,000,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 3,969,000Source |
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | -11,162,000Source | — | -18,978,000Source | — | -86,879,000Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 508,000Source | 1,057,000Source | 3,649,000Source | 2,316,000Source | 6,909,000Source | 5,143,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | -21,010,000Source | 24,493,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,170,000Source | -1,826,000Source | -1,852,000Source | 2,191,000Source | -1,620,000Source | -249,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -3,969,000Source | -8,559,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,067,000Source | -22,425,000Source | -59,917,000Source | -81,177,000Source | 24,895,000Source | -68,878,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 524,000Source | -17,000Source | -123,000Source | 72,408,000Source | -53,969,000Source | -4,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 17,000Source | 123,000Source | 1,132,000Source | — | 4,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -626,000Source | 1,352,000Source | 344,000Source | 62,180,000Source | 1,000Source | 176,129,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -29,073,000Source | 107,247,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,777,000Source | 26,881,000Source | 1,999,000Source | 40,362,000Source | 7,740,000Source | 56,515,000Source | 17,909,000Source | 77,605,000Source | 133,583,000Source | 162,656,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 33,000Source | 50,000Source | 192,000Source | 352,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 421,000Source | 1,115,000Source | 431,000Source | 625,000Source | 508,000Source | 1,057,000Source | 3,649,000Source | 2,316,000Source | 6,909,000Source | 5,143,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 2,800,000Source | 26,900,000Source | 2,000,000Source | 40,400,000Source | 7,700,000Source | 56,500,000Source | 17,900,000Source | 77,600,000Source | 166,900,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 113,000Source | -67,000Source | 0Source | -159,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,239,000Source | 5,203,000Source | 3,354,000Source | 5,560,000Source | 3,907,000Source | 5,445,000Source | 22,138,000Source | 29,525,000Source | 39,787,000Source | 29,393,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 13,064,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 27,764,000Source | 31,700,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | -3,875,000Source | -8,273,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 1,854,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 399,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 44,717,000Source | -12,702,000Source | -9,774,000Source | -11,162,000Source | -9,266,000Source | -18,978,000Source | -60,477,000Source | -86,879,000Source | -19,884,000Source | -336,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 44,717,000Source | -12,702,000Source | — | — | — | — | — | — | -19,884,000Source | -336,000Source |
| Operating ExpensesUSD | — | — | 1,436,000Source | 16,529,000Source | 5,778,000Source | 20,867,000Source | 13,063,000Source | 22,907,000Source | 81,811,000Source | 103,650,000Source | 65,909,000Source | 35,093,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 583,000Source | 442,000Source | 470,000Source | 508,000Source | — | — | — | — | 296,000Source | -60,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 0Source | 146,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 2,286,000Source | 2,392,000Source | 597,000Source | 0Source | 174,962,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,000Source | 2,000Source | 4,000Source | 187,000Source | 1,000Source | 42,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 40,000,000Source | 26,544,000Source |
| Gain (Loss) on Disposition of Other Assets | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 45,300,000Source | 3,400,000Source | — | — | 3,700,000Source | 3,400,000Source | 19,600,000Source | 14,900,000Source | — | — |
| Operating Income (Loss)USD | — | — | 43,814,000Source | -13,144,000Source | -5,778,000Source | -11,670,000Source | -9,334,000Source | -19,510,000Source | -62,179,000Source | -88,731,000Source | -25,909,000Source | -8,549,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 583,000Source | 442,000Source | 470,000Source | 508,000Source | — | — | — | — | 296,000Source | -60,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -23,759,000Source | -8,609,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | -3,875,000Source | -8,273,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 44,717,000Source | -12,702,000Source | -9,774,000Source | -11,162,000Source | -9,266,000Source | -18,978,000Source | -60,477,000Source | -86,879,000Source | -19,884,000Source | -336,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.07Source | -0.31Source | -0.23Source | -0.27Source | -0.22Source | -0.46Source | -1.46Source | -2.59Source | -0.1Source | 0Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.07Source | -0.31Source | -0.23Source | -0.27Source | -0.22Source | -0.46Source | -1.46Source | -2.59Source | -0.1Source | 0Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,788,096Source | 41,588,035Source | 41,788,096Source | 41,543,553Source | 41,771,213Source | 40,938,464Source | 41,456,210Source | 33,524,197Source | 200,546,000Source | 182,323,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,940,292Source | 41,588,035Source | 41,788,096Source | 41,543,553Source | 41,771,213Source | 40,938,464Source | 41,456,210Source | 33,524,197Source | 200,546,000Source | 182,323,000Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 94,000Source | 286,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 661,000Source | 1,693,000Source | 3,354,000Source | 2,837,000Source | 13,000Source | 85,000Source |
| General and Administrative ExpenseUSD | — | — | 1,239,000Source | 5,203,000Source | 3,354,000Source | 5,560,000Source | 3,907,000Source | 5,445,000Source | 22,138,000Source | 29,525,000Source | 39,787,000Source | 29,393,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | 44,717,000Source | -12,702,000Source | -9,774,000Source | -11,162,000Source | -9,266,000Source | -18,978,000Source | — | — | -23,759,000Source | -8,609,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 442,000Source | — | 508,000Source | 68,000Source | 532,000Source | 1,702,000Source | 1,936,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 1,854,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 399,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 44,717,000Source | -12,702,000Source | — | — | — | — | — | — | -19,884,000Source | -336,000Source |
| Operating ExpensesUSD | — | — | 1,436,000Source | 16,529,000Source | 5,778,000Source | 20,867,000Source | 13,063,000Source | 22,907,000Source | 81,811,000Source | 103,650,000Source | 65,909,000Source | 35,093,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Research and Development ExpenseUSD | — | — | 197,000Source | 11,326,000Source | 2,424,000Source | 15,307,000Source | 9,156,000Source | 17,462,000Source | 59,673,000Source | 74,125,000Source | 38,594,000Source | 25,312,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 40,000,000Source | 26,544,000Source |
Offerings
Registration 333-288792
Filing attachments
tmb-20250331xex99d1.htm · S-4 · 2025-07-21
EX-99.1 23 tmb-20250331xex99d1.htm EX-99.1 Exhibit 99.1 Consent to be Named as a Director Carisma Therapeutics Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a…
Read attachment ↗tmb-20250331xex99d2.htm · S-4 · 2025-07-21
EX-99.2 24 tmb-20250331xex99d2.htm EX-99.2 Exhibit 99.2 Consent to be Named as a Director Carisma Therapeutics Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a…
Read attachment ↗tm2518620d1_ex99-1.htm · 8-K · 2025-06-23
EX-99.1 7 tm2518620d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseases OrthoCellix is developing the Phase 3…
Read attachment ↗